MET amplification (gene copy number)

aka MET amplification, MET amp, MET copy number gain, MET/CEP7 ratio, high-level MET amplification, MET GCN >= 10

MET amplification means extra copies of the MET gene, either as a primary driver in a few lung cancers or as the escape route after EGFR inhibitors. No label yet selects on it; trials define it by FISH ratio or copy number.

MET amplification is scored by FISH as MET/CEP7 ratio (high-level at 5 or more in the Camidge classification, or 2 or more with mean copies of 10 or more) or by sequencing as gene copy number (GCN 10 or more is the common trial threshold). It occurs de novo in 1 to 4 percent of NSCLC and arises in 5 to 20 percent of EGFR-mutant cancers progressing on osimertinib, the setting of the MARIPOSA-2 and the SAVANNAH trial of osimertinib plus savolitinib (NCT03778229). No approval names MET amplification as the selection criterion; amivantamab is approved on EGFR status rather than MET, and capmatinib's label covers exon 14 skipping only.

Part ofMET· METOther readoutsc-Met protein overexpression MET exon 14 skipping mutation All readouts

MET: what it is and how drugs act on it · animated schematic, not to scale

Target · the protein and the cell it sits on
Drug · antibody, small molecule, cell or radioligand
Effect · signal, damage or kill

In plain words · A receptor that is either mutated in some lung cancers or amplified as an escape route when other lung cancer drugs fail.

Copy number No approval threshold

What it means for a patient

MET amplification on your report does not yet open an approved treatment on its own. If your lung cancer is EGFR-mutant and grew on osimertinib, it is the reason trials combine a MET inhibitor with the EGFR drug, and your team may discuss those trials or amivantamab, which is approved on EGFR status.

Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.

Scoring rule

MET/CEP7 ratio by FISH (high-level 5 or more) or MET gene copy number by sequencing (trial thresholds of 6 or 10 copies); no label defines a threshold.

“MET amplification (bypass resistance)”
SAVANNAH trial (NCT03778229): MET overexpression and/or amplification defined by IHC 90 percent 3+ or FISH 10 or more copies

Thresholds used in approvals

No approval uses this readout as a threshold. It is defined by SAVANNAH: osimertinib plus savolitinib in MET-amplified or overexpressed EGFR-mutant NSCLC after osimertinib (ClinicalTrials.gov NCT03778229).

Tests that measure it

Tempus xT and xT CDx FoundationOne CDx FoundationOne Liquid CDx Caris MI Profile Guardant360 CDx

Trials that name this readout

Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.